PF-Atlas › Research › In-Vivo CAR

In-Vivo CAR Research (38)

38 papers in the In-Vivo CAR topic, indexed by PF-Atlas from PubMed and global journals.

Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies. · Molecular therapy : the journal of the American Society of Gene Therapy · 2026
Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia. · Journal of experimental & clinical cancer research : CR · 2026
Engineering CAR-Macrophages With Advanced Delivery Systems for Tissue Repair. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
In Vivo mRNA-Lipid Nanoparticle CAR-T Cell Engineering: Advances, Challenges, and Clinical Translation. · Biomedicines · 2026
In vivo CAR-T therapy: The shift from ex vivo culturing to direct in situ immune reprogramming. · International immunopharmacology · 2026
In Situ Generation of Claudin18.2-Specific CAR-T Cells via Lipid Nanoparticle-Mediated mRNA Delivery. · Journal of visualized experiments : JoVE · 2026
Non-viral and mRNA-based strategies for next-generation CAR-T cell therapy. · Pathology, research and practice · 2026
Synergizing artificial intelligence with in vivo CAR-T cell generation: A new paradigm for democratized immunotherapy. · Bio Systems · 2026
In Vivo CAR-T Therapies-A New Era of Programmable Immunity. · International journal of molecular sciences · 2026
Synthetic M13 phage engagers expand CAR-T cell antigen recognition to overcome tumor heterogeneity. · Trends in biotechnology · 2026
Targeted delivery of mRNA to immune cells for in vivo cell therapy. · Drug delivery · 2026
The landscape of genetic medicines for in vivo T cell reprogramming. · Advanced drug delivery reviews · 2026
Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy. · International journal of nanomedicine · 2026
[In vivo CAR-T cells: When the patient becomes their own factory]. · Bulletin du cancer · 2026
Next-generation CAR-T cell therapy against cancer: precision engineering, programmable immunity, and emerging clinical frontiers. · Journal of the Egyptian National Cancer Institute · 2026
In vivo CAR-T cell generation: a production-rate framework linking vector and cellular pharmacology. · Frontiers in immunology · 2026
CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review. · Biomolecules & biomedicine · 2026
The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects. · Signal transduction and targeted therapy · 2026
Next-Generation CAR-T Therapies: From Personalized Anticancer Drugs to Broadly Applicable Disease-Modifying Treatments. · Transplantation and cellular therapy · 2026
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases. · Journal of hematology & oncology · 2026
In Vivo CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation. · Oncology research · 2026
On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors. · Biotechnology advances · 2026
In vivo CAR-T cell therapy: latest updates from 2025 ASH annual meeting. · Journal of hematology & oncology · 2026
Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunotherapy development. · Cancer cell international · 2026
Beyond autologous ex vivo CAR-expressing cell therapies: Toward allogeneic and nucleated cell-free delivery systems of CAR. · Molecular therapy. Oncology · 2026
In vivo transduction of CAR T cells: Pharmacological principles, delivery platforms, and the road to clinical translation. · Advances in pharmacology (San Diego, Calif.) · 2026
Transient T cell therapies. · Advances in pharmacology (San Diego, Calif.) · 2026
Cytokine co-presentation on targeted lipid nanoparticles enhances in vivo T cell engineering. · Biomaterials · 2026
In vivo generation of CD19 CAR T cells for the treatment of mouse systemic lupus erythematosus. · International immunopharmacology · 2026
Lipid Nanoparticles Based Multi-Scale Systemic Immune Programming for Cancer Therapy. · Molecular therapy : the journal of the American Society of Gene Therapy · 2026
In vivo CAR T cells on the highway: a roadmap for the next decade. · Expert opinion on biological therapy · 2026
In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers. · Frontiers in immunology · 2026
Advancing In Vivo Chimeric Antigen Receptor T-Cell Engineering to Accelerate Clinical Translation. · MedComm · 2026
Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy. · Frontiers in pharmacology · 2026
CAR-neutrophils produced in vivo to treat glioma. · Nature biomedical engineering · 2026
In vivo CAR-cell therapy: current challenges and emerging therapeutic advances. · Molecular biomedicine · 2026
In vivo CAR T cell engineering: design principles and open questions. · Trends in cancer · 2026
CAR-M Therapy: From Concept to Clinical Translation in Solid Tumors. · Cells · 2026

Medical disclaimer. Research listings are for information only and are not medical advice.